Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis
Quiroga, Borja (Hospital Universitario de la Princesa (Madrid))
Soler, María José (Hospital Universitari Vall d'Hebron)
Ortiz, Alberto (Instituto de Investigación Carlos III)
Gansevoort, Ron T. (University of Groningen)
Leyva, Alba (VIRCELL SL)
Rojas, José (VIRCELL SL)
de Sequera, Patricia (Hospital Universitario Infanta Leonor)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Introduction. Patients on peritoneal dialysis (PD) present an impaired humoral response against SARS-CoV-2, at least after the initial vaccination and booster dose. Until now, the effect of a fourth dose has not been established. The aim of the present study is to evaluate the long-term dynamics of the humoral response of PD patients to multiple doses of SARS-CoV-2 vaccines, focusing on the effect of the fourth dose. Methods. This is an analysis of the prospective and multicentric SENCOVAC study. We included patients on PD without additional immunosuppression that had received at least 3 SARS-CoV-2 mRNA vaccine doses. We evaluated anti-spike antibody titers after the initial vaccination, third and fourth doses, using prespecified fixed assessments (i. e. , baseline, 28 days, 3, 6, and 12 months after completing the initial vaccine schedule). Breakthrough infections were also collected. Results. We included 164 patients on PD (69% males, 62 ± 13 years old). In patients who had received only two doses, the rates of positive humoral response progressively decreased from 96% at 28 days to 80% at 6 months, as did with anti-spike antibody titers. At 6 months, 102 (62%) patients had received the third vaccine dose. Patients with the third dose had higher rates of positive humoral response (p = 0. 01) and higher anti-spike antibody titers (p < 0. 001) at 6 months than those with only 2 doses. At 12 months, the whole cohort had received 3 vaccine doses, and 44 (27%) patients had an additional fourth dose. The fourth dose was not associated to higher rates of positive humoral response (100 vs. 97%, p = 0. 466) or to statistically significant differences in anti-spike antibody titers as compared to three doses (p = 0. 371) at 12 months. Prior antibody titers were the only predictor for subsequent higher anti-spike antibody titer (B 0. 53 [95%CI 0. 27-0. 78], p < 0. 001). The 2 (1. 2%) patients that developed COVID-19 during follow-up had mild disease. Conclusions. PD presents an acceptable humoral response with three doses of SARS-CoV-2 vaccines that improve the progressive loss of anti-spike antibody titers following two vaccine doses.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Anti-spike antibodies ; Booster ; Chronic kidney disease ; COVID-19 ; Humoral response ; Peritoneal dialysis ; SARS-CoV-2
Publicat a:	Vaccines (Basel), Vol. 10 Núm. 10 (october 2022) , p. 1738, ISSN 2076-393X

DOI: 10.3390/vaccines10101738
PMID: 36298603

10 p, 1.2 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats